Expanding Acalabrutinib to Waldenström Macroglobulinemia
Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing
James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia
Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...
Does Blinatumomab Affect CAR T-Cell Therapy Response?
In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...
Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment
Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory...
With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?
Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.
“Best Survival Data Yet” With Nelarabine in T-Cell ALL
Kimberly P. Dunsmore, MD, discusses results from the largest trial conducted of young patients with newly diagnosed T-cell acute lymphocytic leukemia, which produced survival...
Positive Results With Ivosidenib in IDH1-Mutated AML
Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months...
Allogeneic Transplant Plus NK Cells in High-Risk Myeloma
Dr. Shah discusses natural killer cells for myeloma - a cellular therapy that "kills" without causing graft-versus-host disease.
Evaluating New Myeloma Agent Combinations in Lenalidomide-Refractory Patients
Dr. Chari reports results from a trial of daratumumab plus carfilzomib-dexamethasone in patients with lenalidomide-refractory disease.
Current Issue
July 2018 Bonus Mid-Year Edition
This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.
